

**(Use as many sheets as necessary)**

Sheet	1	of	1
-------	---	----	---

Application Number	09/687,864
Filing Date	October 13, 2000
First Named Inventor	Ledbetter
Art Unit	1648
Examiner Name	Parkin, Jeffrey S
Attorney Docket Number	49076.000002.UTL1

[illegible][illegible]

**Examiner  
Signature**

Date  
Considered

11	12	0
----	----	---

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Collection of information unless it contains a valid OMB control number.

**Compl te if Kn wn**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	09/687,864
Filing Date	10/13/2000
First Named Inventor	Jeffrey A. Ledbetter
Group Art Unit	1648
Examiner Name	
Attorney Docket Number	

## U.S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

~~02/28/2001 JADDUI~~

~~01 EC-126~~

**Examiner  
Signature**

Date	
Considered	

W12 pt

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial in reference to the document to be examined. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


Time will vary depending upon the needs of the individual case. A

number of the patent document. \* Applicable to PCT applications only. \* If English language Translation is attached, possible. \* Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>C complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/687,864		
		Filing Date	10/13/2000		
		First Named Inventor	Jeffrey A. Ledbetter		
		Group Art Unit	1648		
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HOWELL, A.L., ET AL., "Targeting HIV-1 to FcγRIII on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells." J. of Leuk. Biol. 55: 385-391 (1994).	
		ZACHOUANI, H., ET AL., "Induction of antibodies to the human immunodeficiency virus type I by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein." PNAS 92: 631-635 (1995).	
		SYRENGELAS, A.D., ET AL., "DNA Immunization induces protective immunity against B-cell lymphoma." Nature Med. 2: 1038-1041 (1996).	
		LIU, C., ET AL., "FcγRIII on Human B Cells Can Mediate Enhanced Antigen Presentation." Cell. Immunol. 167: 188-194. (1996).	
		LIU, C., ET AL., "FcγRII-Targeted Fusion Proteins Result in Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes." J. Clin. Invest. 98: 2001-2007. (1996).	
		GUYRE, P.M., ET AL., "Increased Potency of Fc-receptor-targeted antigens." Cancer Immunol. Immunother. 45: 146-148 (1997).	

Examiner Signature	Date Considered
	11/12/01


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08B (09-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED  
MAR 06 2001  
EACH CENTER 1600/2900

Substitute for form 1449B/PTO		Compl to if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/687,864
		Filing Date	10/13/2000
		First Named Inventor	Jeffrey A. Ledbetter
		Group Art Unit	1648
		Examiner Name	
Sheet 3 of 3	Attorney Docket Number		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		BOYLE, J.S., ET AL., "Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction." <u>Nature</u> 392: 408-411 (1998).
		GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines." <u>Res. Immunol.</u> 149: 655-660 (1998).
		SERRE, K., ET AL., "Efficient Presentation of Multivalent Antigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen-Specific B Cells." <u>J. Immunol.</u> 161: 6059-6067. (1998).
		RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." <u>J. of Gen Virol.</u> 80: 217-223. (1999).
		BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity." <u>Nature Biotech.</u> 17: 253-258. (1999).

Examiner Signature	Date Considered
	11/12/01

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.